Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies DOI
Meenal Datta, Lisa M. Coussens, Hiroyoshi Nishikawa

et al.

American Society of Clinical Oncology Educational Book, Journal Year: 2019, Volume and Issue: 39, P. 165 - 174

Published: May 1, 2019

Emerging immunotherapeutic approaches have revolutionized the treatment of multiple malignancies. Immune checkpoint blockers (ICBs) enabled never-before-seen success rates in durable tumor control and enhanced survival benefit patients with advanced cancers. However, this effect is not universal, resulting responder nonresponder populations only between, but also within solid types. Although ICBs are thought to be most effective against tumors more genetic mutations higher antigen loads, always case for all cancers or a cancer subtype. Furthermore, debilitating sometimes deadly immune-related adverse events (irAEs) resulted from aberrant activation T-cell responses following immunotherapy. Thus, we must identify new ways overcome resistance ICB-based immunotherapies limit irAEs. In fact, preclinical clinical data identified abnormalities microenvironment (TME) that can thwart efficacy such as ICBs. Here, will discuss how reprogramming various facets TME (blood vessels, myeloid cells, regulatory T cells [Tregs]) may TME-instigated mechanisms We applications strategic approach, including recent successful phase III trial combining bevacizumab atezolizumab chemotherapy metastatic nonsquamous non-small cell lung led rapid approval by U.S. Food Drug Administration regimen first-line treatment. Given accelerated testing combined targeted therapies larger numbers cancer, these concepts incorporated into practice improve immunotherapy outcomes.

Language: Английский

Function and Role of Regulatory T Cells in Rheumatoid Arthritis DOI Creative Commons
Qi Jiang,

Guocan Yang,

Qi Liu

et al.

Frontiers in Immunology, Journal Year: 2021, Volume and Issue: 12

Published: April 1, 2021

Rheumatoid arthritis (RA) is a systemic and heterogeneous autoimmune disease with symmetrical polyarthritis as its critical clinical manifestation. The basic cause of diseases the loss tolerance to self or harmless antigens. functional deficiency key immune cells, regulatory T (Treg) has been confirmed in human diseases. pathogenesis RA complex, dysfunction Tregs one proposed mechanisms underlying breakdown self-tolerance leading progression RA. Treg cells are vital component peripheral tolerance, transcription factor Foxp3 plays major immunosuppressive role. Clinical treatment for mainly utilizes drugs alleviate relieve activity, ideal strategy should be re-induce before obvious tissue injury. options. This review will introduce classification, mechanism action, characteristics RA, which provides insights into treatment.

Language: Английский

Citations

177
Tumor microenvironment: The culprit for ovarian cancer metastasis? DOI

Zhongyue Luo,

Qiu Wang, Wayne Bond Lau

et al.

Cancer Letters, Journal Year: 2016, Volume and Issue: 377(2), P. 174 - 182

Published: April 30, 2016

Language: Английский

Citations

174
Treg cells in health and autoimmune diseases: New insights from single cell analysis DOI
Clemens Scheinecker, Lisa Göschl, Michael Bonelli

et al.

Journal of Autoimmunity, Journal Year: 2019, Volume and Issue: 110, P. 102376 - 102376

Published: Dec. 17, 2019

Language: Английский

Citations

172
Computational Models of Interoception and Body Regulation DOI
Frederike H. Petzschner, Sarah N. Garfinkel, Martin P. Paulus

et al.

Trends in Neurosciences, Journal Year: 2020, Volume and Issue: 44(1), P. 63 - 76

Published: Dec. 29, 2020

Language: Английский

Citations

163
Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies DOI
Meenal Datta, Lisa M. Coussens, Hiroyoshi Nishikawa

et al.

American Society of Clinical Oncology Educational Book, Journal Year: 2019, Volume and Issue: 39, P. 165 - 174

Published: May 1, 2019

Emerging immunotherapeutic approaches have revolutionized the treatment of multiple malignancies. Immune checkpoint blockers (ICBs) enabled never-before-seen success rates in durable tumor control and enhanced survival benefit patients with advanced cancers. However, this effect is not universal, resulting responder nonresponder populations only between, but also within solid types. Although ICBs are thought to be most effective against tumors more genetic mutations higher antigen loads, always case for all cancers or a cancer subtype. Furthermore, debilitating sometimes deadly immune-related adverse events (irAEs) resulted from aberrant activation T-cell responses following immunotherapy. Thus, we must identify new ways overcome resistance ICB-based immunotherapies limit irAEs. In fact, preclinical clinical data identified abnormalities microenvironment (TME) that can thwart efficacy such as ICBs. Here, will discuss how reprogramming various facets TME (blood vessels, myeloid cells, regulatory T cells [Tregs]) may TME-instigated mechanisms We applications strategic approach, including recent successful phase III trial combining bevacizumab atezolizumab chemotherapy metastatic nonsquamous non-small cell lung led rapid approval by U.S. Food Drug Administration regimen first-line treatment. Given accelerated testing combined targeted therapies larger numbers cancer, these concepts incorporated into practice improve immunotherapy outcomes.

Language: Английский

Citations

162